Progressive multifocal leukoencephalopathy after autologous peripheral blood stem cell transplantation in a patient with multiple myeloma treated with combination therapy
详细信息 查看全文
- 作者：Kazuki Yokokawaa ; 1 ; kyokokawa@sapmed.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Shin Hisaharaa ; 1 ; hisahara@sapmed.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Yousuke Matsuuraa ; b ; darumanomiya@yahoo.co.jp" class="auth_mail" title="E-mail the corresponding author ; Kazuna Ikedaa ; kazuna24@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Emiko Tsudaa ; tsudaemi@sapmed.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Masaki Saitoha ; msaitoh@sapmed.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Kazuo Nakamichic ; nakamich@nih.go.jp" class="auth_mail" title="E-mail the corresponding author ; Masayuki Saijoc ; msaijo@nih.go.jp" class="auth_mail" title="E-mail the corresponding author ; Yusuke Kamiharad ; y-kamihara@sapmed.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Tsutomu Satod ; tsutomus@sapmed.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Jun Kawamataa ; jkawamata@sapmed.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Shun Shimohamaa ; shimoha@sapmed.ac.jp" class="auth_mail" title="E-mail the corresponding author
- 关键词：Progressive multifocal leukoencephalopathy (PML) ; JC virus (JCV) ; Multiple myeloma (MM) ; Autologous peripheral blood stem cell transplantation (auto-PBSCT) ; Immunosuppression ; CD34+ cell
- 刊名：Journal of the Neurological Sciences
- 出版年：2016
- 出版时间：15 September 2016
- 年：2016
- 卷：368
- 期：Complete
- 页码：304-306
- 全文大小：369 K
文摘
- •
An unusual case of progressive multifocal leukoencephalopathy with multiple myeloma
- •
The patient was treated with cyclophosphamide and bortezomib.
- •
Auto peripheral blood stem cell transplantation (auto-PBSCT) was performed.
- •
Treatment with mefloquine and mirtazapine resulted in improvement of MRI findings.
- •
Susceptibility of CD34+ peripheral blood stem cells to JCV is discussed.